{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:11:05Z","timestamp":1785352265505,"version":"3.55.0"},"reference-count":45,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"North Carolina Translational and Clinical Sciences Institute","award":["UM1TR004406"],"award-info":[{"award-number":["UM1TR004406"]}]},{"DOI":"10.13039\/100011072","name":"Center for AIDS Research, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["P30AI050410"],"award-info":[{"award-number":["P30AI050410"]}],"id":[{"id":"10.13039\/100011072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2020143"],"award-info":[{"award-number":["2020143"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Background: Long-acting injectable (LAI) cabotegravir\/rilpivirine (CAB\/RPV) extends dosing intervals from daily to every 8\u00a0weeks. Equitable implementation requires anticipating and addressing barriers to use. We described LAI-CAB\/RPV eligibility and initiation among persons with HIV (PWH) receiving care at a Southeastern US academic medical center. Methods: We included PWH \u226518\u00a0years, in care 01\/01\/2020-12\/31\/2021, and participating in the UNC CFAR HIV Clinical Cohort. We characterized LAI-CAB\/RPV eligibility, compared those with and without recent detectable viral load (VL), and described clinical outcomes on LAI-CAB\/RPV. Results: Among 1672 PWH, 425 (25.4%) had LAI-CAB\/RPV drug-resistance. Among 1238 LAI-eligible PWH, 8.9% had detectable VL. Median age was 53 (interquartile range 40, 61), 54.6% were non-Hispanic Black, and 73.6% male. Over one-third lived &gt;50 miles from clinic, one-fifth were uninsured, and 7.4% reported hazardous alcohol use. Gaps in care (prior 12-month) were more common among PWH with detectable VL versus suppressed (23.1% vs 13.9%, p = 0.03). 6\/47 initiated LAI-CAB\/RPV had detectable VL prior to injection; &gt;95% sustained suppression and those with detectable VL had a rapid decline in viremia. Conclusions: Three-quarters of PWH were eligible for LAI-CAB\/RPV, but equitable implementation may require addressing challenges such as distance to care, inconsistent care engagement, and other comorbid conditions, particularly for PWH with viremia.<\/jats:p>","DOI":"10.1177\/09564624241289998","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T12:39:04Z","timestamp":1728045544000},"page":"47-55","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Characterizing long-acting injectable antiretroviral therapy eligibility and initiation at a safety net academic medical center in the southeastern United States"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1571-6576","authenticated-orcid":false,"given":"Sarah E","family":"Rutstein","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lopez","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8505-9268","authenticated-orcid":false,"given":"Thibaut","family":"Davy-Mendez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA"},{"name":"Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Huffstetler","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Perhac","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina Hospitals and Health Systems, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbarajean","family":"Turner","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina Hospitals and Health Systems, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J","family":"Eron","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Go","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E","family":"Farel","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Ping","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Napravnik","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA"},{"name":"Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"bibr1-09564624241289998","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV 2022. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf"},{"key":"bibr2-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.21167"},{"key":"bibr3-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7954"},{"key":"bibr4-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.1343"},{"key":"bibr5-09564624241289998","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2019.305380"},{"key":"bibr6-09564624241289998","unstructured":"Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data United States and 6 dependent areas, 2019 2021; 26. HIV surveillance supplemental report 2021. https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html"},{"key":"bibr7-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000577"},{"key":"bibr8-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001125"},{"key":"bibr9-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab330"},{"key":"bibr10-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2008.0141"},{"key":"bibr11-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32666-0"},{"key":"bibr12-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00184-3"},{"key":"bibr13-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003025"},{"key":"bibr14-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac631"},{"key":"bibr15-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad511"},{"key":"bibr16-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2020.1742869"},{"key":"bibr17-09564624241289998","first-page":"1","volume":"14","author":"Dandachi D","year":"2020","journal-title":"AIDS Care"},{"key":"bibr18-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2018.0198"},{"key":"bibr19-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00031-5"},{"key":"bibr20-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1016\/j.jana.2012.08.007"},{"key":"bibr21-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac455"},{"key":"bibr22-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac716"},{"key":"bibr23-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1080\/09540120600838928"},{"key":"bibr24-09564624241289998","unstructured":"Data access - urban rural classification scheme for counties. 2022. https:\/\/www.cdc.gov\/nchs\/data_access\/urban_rural.html"},{"key":"bibr25-09564624241289998","unstructured":"Performance measure: gap in HIV medical visits. https:\/\/ryanwhite.hrsa.gov\/grants\/performance-measure-portfolio\/core-measures\/gap-in-hiv-medical-visits"},{"key":"bibr26-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2008.06.026"},{"key":"bibr27-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.16.1789"},{"key":"bibr28-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-006-9078-6"},{"key":"bibr29-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1080\/09540120050042891"},{"key":"bibr30-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-013-0437-9"},{"key":"bibr31-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000225"},{"key":"bibr32-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-018-2103-8"},{"key":"bibr33-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1007\/s10900-017-0325-8"},{"key":"bibr34-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26003"},{"key":"bibr35-09564624241289998","unstructured":"Meissner E. At-home vs. in-clinic receipt of cabotegravir and rilpivirine long-acting: an implementation science trial."},{"key":"bibr36-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1080\/13691058.2020.1752397"},{"key":"bibr37-09564624241289998","first-page":"1","volume":"19","author":"Koren DE","year":"2020","journal-title":"J Int Assoc Phys AIDS Care"},{"key":"bibr38-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2017.0125"},{"key":"bibr39-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003239"},{"key":"bibr40-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00291-0"},{"key":"bibr41-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00025-5"},{"key":"bibr42-09564624241289998","unstructured":"Chen W, Gandhi M, Sax P, et al. Projected benefits of long-acting ART (LA-ART) in PWH viremic not taking oral therapy 2023."},{"key":"bibr43-09564624241289998","unstructured":"Rana AI, Bao Y, Zheng L, et al. Long-acting injectable CAB\/RPV is superior to oral ART in PWH with adherence challenges: actg A5359. March 2024, Denver CO."},{"key":"bibr44-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13370"},{"key":"bibr45-09564624241289998","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127950"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624241289998","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624241289998","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624241289998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:46:08Z","timestamp":1777675568000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624241289998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1177\/09564624241289998"],"URL":"https:\/\/doi.org\/10.1177\/09564624241289998","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]}}}